Piper Sandler Raises ACNB Target to $72 From $71
Valid market news retained in the public archive without immediate LiveCast distribution.
Related stories
DaVita Repurchased 382,563 Shares From Berkshire Hathaway
SEC filings show Berkshire Hathaway still owned about 28.3 million DaVita shares following the repurchase.
M impact | EQUITY | Oct 29, 2026, 09:45 PM UTC
Alphabet Shares Fall Nearly 13% as New York Stocks Decline
New York stocks closed lower as technology shares retreated, with Alphabet falling nearly 13%.
H impact | EQUITY | Oct 29, 2026, 09:41 PM UTC
Saba Capital Management Reports $10,816.56 Acquisition of BNY Mellon Municipal Bond Fund Shares
Saba Capital Management reported acquiring $10,816.56 in common shares of BNY Mellon Strategic Municipal Bond Fund.
M impact | EQUITY | Oct 29, 2026, 09:41 PM UTC
Veralto Q3 Adjusted Earnings and Revenue Rise, 2026 Outlook Lifted
Veralto reported higher Q3 adjusted earnings and revenue and lifted its 2026 outlook.
M impact | EQUITY | Oct 29, 2026, 09:36 PM UTC
Amazon CEO Sees Compute Capacity Demand Visibility Through 2029
Amazon’s CEO said the company has very good visibility into compute capacity demand in 2027 and 2028, and some of 2029.
M impact | EQUITY | Oct 29, 2026, 09:35 PM UTC
Argus Research Upgrades Biogen to Buy, Sets $280 Price Target
Argus Research upgraded Biogen to Buy from Hold and set a $280 price target. The target implies 12.2% upside from the Oct. 29 close of $249.65.
M impact | EQUITY | Oct 29, 2026, 09:34 PM UTC